Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTNP
CUSIPN/A
Phone650-244-4990
Debt
Debt-to-Equity Ratio-2.70
Current Ratio1.76
Quick Ratio1.21
Price-To-Earnings
Trailing P/E Ratio-0.71
Forward P/E Ratio-1.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$220,000.00
Price / Sales48.18
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book12.50
Profitability
EPS (Most Recent Fiscal Year)($0.70)
Net Income$-14,300,000.00
Net Margins-295.69%
Return on Equity-1,659.34%
Return on Assets-143.63%
Miscellaneous
Employees13
Outstanding Shares21,200,000
Market Cap$12.09 million
Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions
What is Titan Pharmaceuticals' stock symbol?
Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."
How were Titan Pharmaceuticals' earnings last quarter?
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) released its quarterly earnings data on Tuesday, August, 14th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.09. The specialty pharmaceutical company earned $2.67 million during the quarter, compared to analyst estimates of $0.07 million. Titan Pharmaceuticals had a negative net margin of 295.69% and a negative return on equity of 1,659.34%. View Titan Pharmaceuticals' Earnings History.
When is Titan Pharmaceuticals' next earnings date?
What price target have analysts set for TTNP?
1 brokers have issued twelve-month target prices for Titan Pharmaceuticals' stock. Their predictions range from $2.00 to $2.00. On average, they anticipate Titan Pharmaceuticals' share price to reach $2.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price. View Analyst Price Targets for Titan Pharmaceuticals.
What is the consensus analysts' recommendation for Titan Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Titan Pharmaceuticals.
Who are some of Titan Pharmaceuticals' key competitors?
Some companies that are related to Titan Pharmaceuticals include Genocea Biosciences (GNCA), BIONDVAX PHARMA/S (BVXV), Proteon Therapeutics (PRTO), CytRx (CYTR), Vical (VICL), Arsanis (ASNS), aTyr Pharma (LIFE), Vaxart (VXRT), Genetic Technologies (GENE), Microbot Medical (MBOT), Neuralstem (CUR), TrovaGene (TROV), Mymetics (MYMX), Windtree Therapeutics (WINT) and Enzon Pharmaceuticals (ENZN).
Who are Titan Pharmaceuticals' key executives?
Titan Pharmaceuticals' management team includes the folowing people:
- Dr. Marc Rubin, Exec. Chairman (Age 63)
- Mr. Sunil Bhonsle, CEO, Pres, Sec. & Director (Age 68)
- Dr. Katherine L. Beebe-Devarney Ph.D., Exec. VP & Chief Scientific Officer
- Brian E. Crowley, VP of Fin.
Has Titan Pharmaceuticals been receiving favorable news coverage?
Media headlines about TTNP stock have trended somewhat positive on Thursday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Titan Pharmaceuticals earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Titan Pharmaceuticals.
How do I buy shares of Titan Pharmaceuticals?
Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Titan Pharmaceuticals' stock price today?
One share of TTNP stock can currently be purchased for approximately $0.50.
How big of a company is Titan Pharmaceuticals?
Titan Pharmaceuticals has a market capitalization of $12.09 million and generates $220,000.00 in revenue each year. The specialty pharmaceutical company earns $-14,300,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Titan Pharmaceuticals employs 13 workers across the globe.
How can I contact Titan Pharmaceuticals?
Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]
MarketBeat Community Rating for Titan Pharmaceuticals (NASDAQ TTNP)
MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
